

November 26, 2025

National Stock Exchange of India Limited  
Exchange Plaza,  
Plot No. C/1, G Block,  
Bandra Kurla Complex, Bandra (E)  
Mumbai – 400 051

BSE Limited  
Corporate Relationship Department  
Phiroze Jeejeebhoy Towers  
Dalal Street  
Mumbai – 400 001

Symbol: LALPATHLAB

Scrip Code: 539524

**Sub: Press Release**

**Ref: Compliances under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“Listing Regulations”)**

Dear Sir/ Madam,

Pursuant to Regulation 30 of the Listing Regulations, please find enclosed herewith the Press Release titled “*Dr. Lal PathLabs Strengthens Autoimmune Diagnosis with India’s First Comprehensive Complement Lab*”.

We request you to please take the same on record.

Thanking You,  
Yours Faithfully,

**For Dr. Lal PathLabs Limited**

**Vinay Gujral**  
**Company Secretary & Compliance Officer**  
*Encl.: As above*

## Dr. Lal PathLabs Strengthens Autoimmune Diagnosis with India's First Comprehensive Complement Lab

- Dr. Lal PathLabs has launched India's First Comprehensive Complement Testing Laboratory, offering several tests made available in the country for the very first time.
- A 2024 study report suggested 30% increase in autoimmune disorders post-pandemic. People aged 31–45 years showed the sharpest rise.<sup>1</sup>
- Another report suggested nearly 70% of autoimmune patients in India are women, as highlighted at IRACON 2025. Hormonal and genetic factors contribute significantly.<sup>2</sup>

**New Delhi, [26 November, 2025]:** Dr. Lal PathLabs (DLPL), one of India's leading diagnostic networks, today announced the launch of **India's first dedicated Complement Testing Laboratory**, strengthening its position as India's leading hub for autoimmune diagnostics. This advanced facility brings globally benchmarked complement assays to Indian patients, several for the first time in the country, helping doctors diagnose autoimmune, kidney, and recurrent infection related conditions **faster, more accurately, and at earlier stages**.

### Why Complement Testing Matters Today

Autoimmune and inflammatory diseases are increasingly being recognized across India, with more patients seeking care for conditions that often begin with vague, overlapping symptoms. Many individuals experience fever, joint pain, swelling, fatigue, or kidney-related issues and may consult multiple doctors before receiving a clear diagnosis.

These delays occur because autoimmune diseases can progress silently, affecting vital organs long before symptoms become obvious. Complement testing helps uncover the underlying immune disturbance and provide clarity on **why** these symptoms occur and enabling earlier, more accurate diagnosis and treatment.

The complement system is a group of blood proteins that help fight infections, clear damaged cells, and protect vital organs. When this system is weak, the body, especially children, becomes prone to repeated or severe infections. When it becomes overactive, it can mistakenly attack healthy tissues, contributing to conditions such as lupus, certain kidney diseases like C3 glomerulopathy and atypical haemolytic uremic syndrome (HUS), vasculitis, rheumatoid arthritis, transplant rejection, and even sepsis.

Because the complement system can malfunction in different ways, understanding its activity is crucial. Complement testing measures important immune proteins such as C3, C4, and C5, helping identify whether the immune response is overactive, underactive, or malfunctioning, a vital step in diagnosing and managing autoimmune diseases early.

*"Complement testing has long been underrepresented in India's diagnostic landscape. By introducing functional and antibody-based complement assays such as C1q, C5, Factor B, Factor H antibody, AH50, and C1 INH functional, many for the first time in the country, we are enabling earlier and more precise insights into immune-mediated disease. This bridges the gap between research and routine clinical care."* **Said Dr. Vandana Lal, Executive Director, Dr. Lal PathLabs.**

*"As a pioneer in specialized diagnostics, we are proud to offer India's first comprehensive complement testing platform. This marks a major step toward faster diagnosis, better treatment decisions, and improved outcomes for millions living with autoimmune and kidney diseases"* **said Mr. Shankha Banerjee, CEO, Dr. Lal PathLabs.**

The Complement Laboratory is equipped with state-of-the-art immunoturbidimetric and ELISA platforms and adheres to CAP and NABL accreditation standards. For patients living with autoimmune or inflammatory conditions, the launch offers greater clarity and control over disease management. Early and precise diagnosis means better treatment outcomes, reduced healthcare costs, and improved quality of life.

#### **About Dr. Lal PathLabs Limited**

Dr. Lal PathLabs is a provider of diagnostic and related healthcare tests and services in India. Through its' integrated, nationwide network, the company offer patients and healthcare providers a broad range of diagnostic and related healthcare tests and services for use in core testing, patient diagnosis and the prevention, monitoring and treatment of disease and other health conditions. As on March 31, 2025 the company has 298 clinical laboratories (including National Reference Lab at Delhi, Regional Reference Lab at Kolkata, Bangalore & Mumbai), 6,607 Patient Service Centers (PSCs) and 12,365 Pick-up Points (PUPs). Its' customers include individual patients, hospitals and other healthcare providers and corporate customers.

---

#### Reference:

<sup>1</sup><https://www.newindianexpress.com/cities/delhi/2024/Oct/22/post-covid-30-per-cent-rise-in-autoimmune-disorders-among-indian-population-study>

<sup>2</sup><https://timesofindia.indiatimes.com/city/delhi/nearly-70-of-autoimmune-patients-are-women-blame-it-on-hormones/articleshow/124535839.cms>